Lipocine (NASDAQ:LPCN) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?

Lipocine Inc. (NASDAQ:LPCN) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.97 and traded as high as $3.14. Lipocine shares last traded at $3.11, with a volume of 9,744 shares.

Analyst Upgrades and Downgrades

LPCN has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lipocine in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Lipocine in a report on Wednesday, August 20th. Finally, Alliance Global Partners upgraded shares of Lipocine to a “strong-buy” rating in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Lipocine Stock Performance

The company has a market capitalization of $16.86 million, a price-to-earnings ratio of -3.57 and a beta of 1.29. The firm has a 50-day simple moving average of $2.97 and a two-hundred day simple moving average of $3.14.

Lipocine (NASDAQ:LPCN) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). The firm had revenue of $0.62 million during the quarter, compared to analyst estimates of $1.00 million.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.